A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders: From ancient tradition to modern-day medicine

Natascia Brondino, Annalisa De Silvestri, Simona Re, Niccolò Lanati, Pia Thiemann, Anna Verna, Enzo Emanuele, Pierluigi Politi

Research output: Contribution to journalArticle

Abstract

Ginkgo biloba (Gb) has demonstrated antioxidant and vasoactive properties as well as clinical benefits in several conditions such as ischemia, epilepsy, and peripheral nerve damage. Additionally, Gb is supposed to act as potential cognitive enhancer in dementia. So far, several trials have been conducted to investigate the potential effectiveness of Gb in neuropsychiatric conditions. However, the results of these studies remain controversial. We conducted a systematic review and a meta-analysis of three randomised controlled trials in patients with schizophrenia and eight randomised controlled trials in patients with dementia. Gb treatment reduced positive symptoms in patients with schizophrenia and improved cognitive function and activities of daily living in patients with dementia. No effect of Gb on negative symptoms in schizophrenic patients was found. The general lack of evidence prevents drawing conclusions regarding Gb effectiveness in other neuropsychiatric conditions (i.e., autism, depression, anxiety, attention-deficit hyperactivity disorder, and addiction). Our data support the use of Gb in patients with dementia and as an adjunctive therapy in schizophrenic patients.

Original languageEnglish
Article number915691
JournalEvidence-based Complementary and Alternative Medicine
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Ginkgo biloba
Modern 1601-history
Meta-Analysis
Dementia
Schizophrenia
Randomized Controlled Trials
Nootropic Agents
Attention Deficit Disorder with Hyperactivity
Activities of Daily Living
Autistic Disorder
Peripheral Nerves
Cognition
Epilepsy
Ischemia
Anxiety
Antioxidants
Depression
Therapeutics

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders : From ancient tradition to modern-day medicine. / Brondino, Natascia; De Silvestri, Annalisa; Re, Simona; Lanati, Niccolò; Thiemann, Pia; Verna, Anna; Emanuele, Enzo; Politi, Pierluigi.

In: Evidence-based Complementary and Alternative Medicine, Vol. 2013, 915691, 2013.

Research output: Contribution to journalArticle

Brondino, Natascia ; De Silvestri, Annalisa ; Re, Simona ; Lanati, Niccolò ; Thiemann, Pia ; Verna, Anna ; Emanuele, Enzo ; Politi, Pierluigi. / A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders : From ancient tradition to modern-day medicine. In: Evidence-based Complementary and Alternative Medicine. 2013 ; Vol. 2013.
@article{0b4591de705a41109e8dec4e327b4759,
title = "A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders: From ancient tradition to modern-day medicine",
abstract = "Ginkgo biloba (Gb) has demonstrated antioxidant and vasoactive properties as well as clinical benefits in several conditions such as ischemia, epilepsy, and peripheral nerve damage. Additionally, Gb is supposed to act as potential cognitive enhancer in dementia. So far, several trials have been conducted to investigate the potential effectiveness of Gb in neuropsychiatric conditions. However, the results of these studies remain controversial. We conducted a systematic review and a meta-analysis of three randomised controlled trials in patients with schizophrenia and eight randomised controlled trials in patients with dementia. Gb treatment reduced positive symptoms in patients with schizophrenia and improved cognitive function and activities of daily living in patients with dementia. No effect of Gb on negative symptoms in schizophrenic patients was found. The general lack of evidence prevents drawing conclusions regarding Gb effectiveness in other neuropsychiatric conditions (i.e., autism, depression, anxiety, attention-deficit hyperactivity disorder, and addiction). Our data support the use of Gb in patients with dementia and as an adjunctive therapy in schizophrenic patients.",
author = "Natascia Brondino and {De Silvestri}, Annalisa and Simona Re and Niccol{\`o} Lanati and Pia Thiemann and Anna Verna and Enzo Emanuele and Pierluigi Politi",
year = "2013",
doi = "10.1155/2013/915691",
language = "English",
volume = "2013",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders

T2 - From ancient tradition to modern-day medicine

AU - Brondino, Natascia

AU - De Silvestri, Annalisa

AU - Re, Simona

AU - Lanati, Niccolò

AU - Thiemann, Pia

AU - Verna, Anna

AU - Emanuele, Enzo

AU - Politi, Pierluigi

PY - 2013

Y1 - 2013

N2 - Ginkgo biloba (Gb) has demonstrated antioxidant and vasoactive properties as well as clinical benefits in several conditions such as ischemia, epilepsy, and peripheral nerve damage. Additionally, Gb is supposed to act as potential cognitive enhancer in dementia. So far, several trials have been conducted to investigate the potential effectiveness of Gb in neuropsychiatric conditions. However, the results of these studies remain controversial. We conducted a systematic review and a meta-analysis of three randomised controlled trials in patients with schizophrenia and eight randomised controlled trials in patients with dementia. Gb treatment reduced positive symptoms in patients with schizophrenia and improved cognitive function and activities of daily living in patients with dementia. No effect of Gb on negative symptoms in schizophrenic patients was found. The general lack of evidence prevents drawing conclusions regarding Gb effectiveness in other neuropsychiatric conditions (i.e., autism, depression, anxiety, attention-deficit hyperactivity disorder, and addiction). Our data support the use of Gb in patients with dementia and as an adjunctive therapy in schizophrenic patients.

AB - Ginkgo biloba (Gb) has demonstrated antioxidant and vasoactive properties as well as clinical benefits in several conditions such as ischemia, epilepsy, and peripheral nerve damage. Additionally, Gb is supposed to act as potential cognitive enhancer in dementia. So far, several trials have been conducted to investigate the potential effectiveness of Gb in neuropsychiatric conditions. However, the results of these studies remain controversial. We conducted a systematic review and a meta-analysis of three randomised controlled trials in patients with schizophrenia and eight randomised controlled trials in patients with dementia. Gb treatment reduced positive symptoms in patients with schizophrenia and improved cognitive function and activities of daily living in patients with dementia. No effect of Gb on negative symptoms in schizophrenic patients was found. The general lack of evidence prevents drawing conclusions regarding Gb effectiveness in other neuropsychiatric conditions (i.e., autism, depression, anxiety, attention-deficit hyperactivity disorder, and addiction). Our data support the use of Gb in patients with dementia and as an adjunctive therapy in schizophrenic patients.

UR - http://www.scopus.com/inward/record.url?scp=84879317704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879317704&partnerID=8YFLogxK

U2 - 10.1155/2013/915691

DO - 10.1155/2013/915691

M3 - Article

C2 - 23781271

AN - SCOPUS:84879317704

VL - 2013

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 915691

ER -